PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 18 filers reported holding PROQR THRAPEUTICS N V in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $224,000 | -5.1% | 72,796 | -0.4% | 0.00% | – |
| Q4 2017 | $236,000 | -40.3% | 73,096 | -10.3% | 0.00% | – |
| Q3 2017 | $395,000 | -0.8% | 81,494 | +6.5% | 0.00% | – |
| Q2 2017 | $398,000 | +4.2% | 76,494 | 0.0% | 0.00% | – |
| Q1 2017 | $382,000 | +1.9% | 76,494 | 0.0% | 0.00% | – |
| Q4 2016 | $375,000 | -26.5% | 76,494 | 0.0% | 0.00% | -100.0% |
| Q3 2016 | $510,000 | +37.8% | 76,494 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $370,000 | -3.1% | 76,494 | -2.3% | 0.00% | 0.0% |
| Q1 2016 | $382,000 | -43.8% | 78,294 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $680,000 | -43.9% | 78,294 | -6.0% | 0.00% | -50.0% |
| Q3 2015 | $1,213,000 | -10.9% | 83,250 | +2.0% | 0.00% | 0.0% |
| Q2 2015 | $1,361,000 | -18.0% | 81,640 | +7.7% | 0.00% | 0.0% |
| Q1 2015 | $1,659,000 | +1.5% | 75,800 | +0.5% | 0.00% | -33.3% |
| Q4 2014 | $1,634,000 | – | 75,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 748,861 | $6,815,000 | 2.37% |
| Opus Point Partners Management, LLC | 138,461 | $1,260,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,722,950 | $33,879,000 | 1.81% |
| Kerrisdale Advisers, LLC | 465,580 | $4,237,000 | 1.52% |
| DAFNA Capital Management LLC | 261,521 | $2,380,000 | 0.90% |
| SPHERA FUNDS MANAGEMENT LTD. | 470,000 | $4,277,000 | 0.58% |
| Artal Group S.A. | 1,300,000 | $11,830,000 | 0.48% |
| Orbimed Advisors | 1,382,502 | $12,581,000 | 0.20% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 56,000 | $511,000 | 0.19% |
| ALTRINSIC GLOBAL ADVISORS LLC | 201,360 | $1,832,000 | 0.08% |